Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study

A large interindividual variability has been observed in anti Programmed cell Death 1 (anti-PD1) therapies efficacy. The aim of this study is to assess the correlation of soluble PD-1 (sPD-1), soluble Programmed cell Death Ligand 1 (sPD-L1), Vascular Endothelial Growth Factor A (VEGFA), soluble CD40...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiako Meyo, Manuela, Jouinot, Anne, Giroux-Leprieur, Etienne, Fabre, Elizabeth, Wislez, Marie, Alifano, Marco, Leroy, Karen, Boudou-Rouquette, Pascaline, Tlemsani, Camille, Khoudour, Nihel, Arrondeau, Jennifer, Thomas-Schoemann, Audrey, Blons, Hélène, Mansuet-Lupo, Audrey, Damotte, Diane, Vidal, Michel, Goldwasser, François, Alexandre, Jérôme, Blanchet, Benoit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072584/
https://www.ncbi.nlm.nih.gov/pubmed/32085544
http://dx.doi.org/10.3390/cancers12020473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072584/
https://www.ncbi.nlm.nih.gov/pubmed/32085544
http://dx.doi.org/10.3390/cancers12020473

Ejemplares similares